Drug intelligence / Profile preview

ALY-102

Development stage: Preclinical
Lead developer: Alys Pharmaceuticals
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

ALY-102 is a topical therapeutic candidate being developed by Alys Pharmaceuticals for the treatment of chronic hand eczema and atopic dermatitis. The drug utilizes a proprietary CMAP (Crystalline Micro-Array Particle) particle suspension gel delivery platform, which is designed to optimize the delivery of the active pharmaceutical ingredient into the skin. Originally part of the Granular Therapeutics pipeline before its acquisition by Alys, ALY-102 is currently in IND-enabling studies, with a Phase 1/2 clinical trial application expected in the second half of 2026.

Targets

IL17F (Interleukin 17F)IL-17A (Interleukin-17A)

Beyond the preview

Go deeper on ALY-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALY-102.

Explore the full profile